Dendrocyte expressed seven transmembrane protein (DCSTAMP)

Dendrocyte expressed seven transmembrane protein (DCSTAMP) is a seven-pass transmembrane protein primarily expressed in dendritic cells and osteoclast precursors[2][3][4]. It is a master regulator of cell–cell fusion during osteoclastogenesis, essential for forming multinucleated osteoclasts that resorb bone[1][2][3][4]. DCSTAMP also contributes to myeloid cell differentiation, regulates dendritic cell functions (including antigen presentation and phagocytosis), and is involved in maintenance of immune self-tolerance[4]. Its disruption results in abnormal bone formation (such as osteopetrosis) and impaired immune responses[1][4]. DCSTAMP’s therapeutic relevance is mainly in bone disorder contexts; it is actively studied in relation to Paget’s disease of bone and other conditions involving dysregulated osteoclast activity[4]. Key regulators and interacting proteins include CCN2, OS9, Pin1, Tal-1, and microRNAs such as miR-7b[1][2]. Although no drugs are currently approved that directly target DCSTAMP, its pivotal role makes it a candidate for future bone-resorption disease treatments[2][4].

Other names

DC-STAMPDendritic cell-specific transmembrane proteinTM7SF4hDC-STAMPFINDIL-4-induced proteinTransmembrane 7 superfamily member 4DCSTP_HUMAN (UniProt)

Inhibition or modulation of DCSTAMP expression or function can block osteoclast precursor fusion and thereby inhibit osteoclastogenesis—potentially useful for treating bone resorption disorders[1][2].